← All drugs Report issue

ineo-vac-p01

Vaccineexperimental

Clinical trial activity

12 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

12

Phase 2

4

Phase 3

0

Phase 4

0

Earliest trial started Oct 24, 2017 (NCT03645148)

Timeline

2010s

Jan 1, 2017
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Tumor antigensImmunity, active
immunity, active - tumor antigens

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06956716	Phase 1/Phase 2 (Phase 2)	Apr 9, 2025	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT06995105	Phase 1/Phase 2 (Phase 2)	Apr 9, 2025	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT06888648	Phase 1/Phase 2 (Phase 2)	Apr 1, 2025	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT06888674	Phase 1/Phase 2 (Phase 2)	Apr 1, 2025	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT06026774	Phase 1	Sep 8, 2023	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT06019702	Phase 1	Sep 8, 2023	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT06026800	Phase 1	Sep 8, 2023	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT05307835	Phase 1	Dec 2, 2021	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT04810910	Phase 1	Mar 30, 2021	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT04864379	Phase 1	Sep 3, 2020	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT03662815	Phase 1	Feb 7, 2018	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University
NCT03645148	Phase 1	Oct 24, 2017	Hangzhou Neoantigen Therapeutics Co., Ltd., Zhejiang University

Showing 12 of 12 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Hangzhou Neoantigen Therapeutics Co., Ltd.	Government	12	0	2	2017
Zhejiang University	Academic/Hospital	12	12	2	2017

2 organizations

Page 1 / 1